Key points from article :
Insilico Medicine has completed a $60 million Series D financing from a syndicate of global investors.
Capital raised will fuel the growth of its advancing pipeline, including its lead program which is currently in a Phase I study.
Proceeds will also fund a fully automated, AI-driven robotic drug discovery laboratory, and fully robotic biological data factory to complement the company’s vast curated data assets.
“It is a testament to the strength of our end-to-end AI platform, which has been validated by many partners,” said Alex Zhavoronkov, Founder and CEO.
Seven programs in its internal pipeline have progressed to the IND-enabling stage.
"We plan to continue expanding the breadth of the pipeline and enhance our AI and robotics capabilities globally," explained Feng Ren, Insilico’s CSO.
Since the launch of its PandaOmics and Chemistry42 in late 2020, nine out of the top 20 pharmaceutical companies, as measured by 2020 revenue, have licensed Insilico’s AI platforms.